# UK Biosimilar Contract Manufacturing Market > UK Biosimilar Contract Manufacturing Market Research Report: Size, Share, Trend Analysis By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Production Technology (Mammalian, Non-Mammalian) and By Applications (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 18.9% - **2024:** $ 541 Million - **2025:** $ 643.25 Million - **2035:** $ 3,632.14 Million - **Key Players:** Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Rentschler Biopharma (DE), KBI Biopharma (US), Amgen (US) **Report ID:** MRFR/Pharma/50107-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-biosimilar-contract-manufacturing-market-51865 --- ## Market Summary ## **UK Biosimilar Contract Manufacturing Market Overview** As per MRFR analysis, the UK Biosimilar Contract Manufacturing Market Size was estimated at 325.06 (USD Million) in 2023. The UK Biosimilar Contract Manufacturing Market Industry is expected to grow from 386.5(USD Million) in 2024 to 2,063.7 (USD Million) by 2035. The UK Biosimilar Contract Manufacturing Market CAGR (growth rate) is expected to be around 16.449% during the forecast period (2025 - 2035). ### **Key UK Biosimilar Contract Manufacturing Market Trends Highlighted** The UK Biosimilar Contract Manufacturing Market is experiencing substantial growth, which is being driven by critical market drivers, including the increasing prevalence of chronic diseases and the rising cost of healthcare. The UK government has demonstrated a dedication to the integration of biosimilars into the healthcare system through its initiatives to encourage their use in order to decrease expenditures on biologics. This regulatory support is fostering a favorable environment for contract manufacturers, facilitating their investment in biosimilar production capabilities. Moreover, the region's production capacity for biosimilars is being increased as a result of the continuous improvements in biomanufacturing technologies, which are resulting in increased efficiency. Opportunities for exploration in the UK market include the potential for collaborations between biotech firms and contract manufacturers, which would enable the firms to capitalise on each other's strengths to expedite the development and production of biosimilars. As a result of the prospective entry of new players into the biosimilar space, existing manufacturers are being compelled to innovate and improve their service offerings, thereby increasing their competitiveness. In recent years, there has been a discernible trend towards a higher acceptability rate of biosimilars among healthcare professionals and patients. This transition is sustained by the initiatives of numerous health organisations and campaigns in the United Kingdom that are designed to inform stakeholders about the safety and efficacy of biosimilars. Furthermore, the increasing demand for advanced manufacturing solutions is being driven by the increasing prominence of personalized medicine, which is further solidifying the position of biosimilars in the UK healthcare market. The future of the UK biosimilar contract manufacturing market is promising as companies align with evolving regulatory frameworks and industry standards. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **UK Biosimilar Contract Manufacturing Market Drivers** #### **Increasing Demand for Cost-Effective Biologics** The growing demand for cost-efficient alternatives to expensive biologics is a significant driver for the UK Biosimilar Contract Manufacturing Market Industry. With the National Health Service (NHS) striving to reduce drug costs amid rising healthcare expenditures, biosimilars present a viable solution, as they are generally 20-30% cheaper than their originator biologics. According to the NHS Long Term Plan, biosimilars could save the healthcare system an estimated 200 million GBP annually by 2025. The influx of manufacturers such as Sandoz and Biocon into the UK market contributes to the availability and variety of biosimilars, facilitating better access for patients and consequently pushing market growth in this sector. #### **Supportive Regulatory Framework** The regulatory environment in the UK is increasingly favorable for the development and approval of biosimilars, driving growth in the UK Biosimilar Contract Manufacturing Market Industry. The Medicines and Healthcare products Regulatory Agency (MHRA) has implemented specific guidelines to streamline the approval process for biosimilars. This supports quicker market entry for new biosimilars, enhancing competition and accessibility. The European Medicines Agency (EMA) has also endorsed a clear pathway for biosimilar approval, which has influenced the UK as it follows similar practices post-Brexit. Consequently, with over 15 biosimilar products currently approved in the UK, this robust regulatory support encourages investment and innovation in biosimilar manufacturing. #### **Rising Incidence of Chronic Diseases** The increasing prevalence of chronic diseases, such as diabetes and cancer, directly fuels the demand for biosimilars in the UK Biosimilar Contract Manufacturing Market Industry. Recent reports indicate that the number of people living with diabetes in the UK has surged to 4.9 million, with projections estimating this number will hit 5.5 million by 2030. This growing patient population necessitates affordable treatment options like biosimilars for biologic medications. Companies like Amgen and Mylan are focusing resources on developing biosimilars targeting chronic disease treatment, thereby addressing patient needs and expanding market penetration. #### **Advancements in Biomanufacturing Technologies** Technological advancements in biomanufacturing processes significantly bolster the growth of the UK Biosimilar Contract Manufacturing Market Industry. Innovations such as single-use bioreactors and process intensification enable manufacturers to achieve higher production efficiency while reducing costs. For instance, recent data suggests that companies adopting these modern technologies can decrease their production costs by up to 30%. As manufacturers like Lonza and WuXi AppTec adopt these cutting-edge processes, the overall viability and attractiveness of entering the biosimilar market increase, which catalyzes further growth in the UK sector. ### **UK Biosimilar Contract Manufacturing Market Segment Insights** #### **Biosimilar Contract Manufacturing Market Product Insights** The UK Biosimilar Contract Manufacturing Market primarily centers around diverse products that play a vital role in the pharmaceutical sector. Within this market, the product segment encompasses crucial categories such as Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins, each catering to distinct therapeutic needs and exhibiting unique characteristics. Recombinant Non-glycosylated Proteins are essential in the production of various biotherapeutics, facilitating treatment for conditions such as hormonal deficiencies and certain types of cancer. Their simple structure not only streamlines the manufacturing process but also contributes to their cost-effectiveness, making them appealing for companies looking to reduce production expenses while maintaining efficacy. In contrast, Recombinant Glycosylated Proteins are indispensable for developing more complex biologic drugs, including enzymes and antibodies, which require precise glycosylation for optimal functionality and therapeutic effects. This sub-segment demonstrates significant advancements, particularly in personalized medicine, where the proper glycosylation can enhance drug efficacy. The demand for such products is further bolstered by the increasing prevalence of chronic diseases within the UK, prompting a greater push for biosimilar options and biologics that can serve as alternatives to expensive monoclonal antibodies. The UK government has been supportive of initiatives aimed at boosting the biosimilar market, recognizing its potential to enhance access to affordable treatments while also driving innovation in the life sciences industry. With the ongoing trend towards personalized medicine and greater focus on biopharmaceutical manufacturing, the UK Biosimilar Contract Manufacturing Market is poised to grow, driven by the need for high-quality, efficient production of both Recombinant Non-glycosylated and Glycosylated Proteins. This growth is fueled by the advantages these products provide in terms of treatment accessibility, cost-reduction in healthcare, and improved patient outcomes, ultimately positioning the UK as a key player in the global biosimilars space. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** #### **Biosimilar Contract Manufacturing Market Production Technology Insights** The Production Technology segment of the UK Biosimilar Contract Manufacturing Market has garnered significant attention due to its pivotal role in the development and production of biosimilars. This segment predominantly consists of two main categories Mammalian and Non-Mammalian production technologies. Mammalian systems are often favored in the production of complex biologics due to their ability to perform post-translational modifications, which are critical for the functionality of many therapeutic proteins. The UK government's initiatives to support biopharmaceutical innovation have reinforced the importance of robust mammalian platforms, thereby enhancing the competitiveness of local manufacturers in the biosimilar space. Conversely, Non-Mammalian technologies, which include microbial systems, are gaining traction for their cost-effectiveness and rapid production capabilities. These systems are especially suitable for simpler proteins and can significantly reduce time-to-market, presenting a strategic advantage in a fast-evolving market. As the UK Biosimilar Contract Manufacturing Market continues to expand, the adoption of advanced production technologies will likely drive efficiency and scalability, responding to the growing demand for affordable biological therapies in the healthcare sector. The emphasis on innovation within these production methodologies reflects the ongoing efforts by industry players to meet regulatory standards and respond to patient needs, ensuring that the UK remains a key player in the global biosimilars landscape. #### **Biosimilar Contract Manufacturing Market Application Insights** The Application segment of the UK Biosimilar Contract Manufacturing Market plays a crucial role in delivering affordable therapeutic solutions across various medical conditions. The Oncology section remains a focal point, driven by the rising prevalence of cancer, necessitating effective biosimilar treatments to improve patient outcomes and reduce healthcare costs. Blood Disorders are also gaining importance due to the growing patient population requiring advanced therapies, promoting the need for sustainable manufacturing solutions. Additionally, Growth Hormonal Deficiency treatment options are seeing increased demand as awareness of hormonal imbalances rises among the population. Chronic and Autoimmune Disorders, including Rheumatoid Arthritis, contribute significantly to the market, influenced by the aging population and advancements in biosimilar technology. The UK government’s focus on enhancing healthcare access supports the growth of these application areas, fostering innovations that enable cost-effective treatment pathways. Overall, the insights from the Application segment indicate a diverse landscape with substantial growth opportunities across multiple therapeutic categories, positioning the UK as a significant player in the global biosimilar market. ### **UK Biosimilar Contract Manufacturing Market Key Players and Competitive Insights** The UK Biosimilar Contract Manufacturing Market is characterized by a complex interplay of factors driving growth and competition. With an increasing shift towards the use of biosimilars as a cost-effective alternative to originator biologics, the market has seen a heightened interest from both established players and new entrants looking to capitalize on this trend. The competitive landscape is marked by companies offering specialized manufacturing capabilities, advanced technologies, and a focus on regulatory compliance to meet the stringent guidelines set forth by health authorities. The demand for biosimilars within the UK has been influenced by the rising pressures to reduce healthcare costs while ensuring patient access to biologic therapies, thus presenting opportunities for growth and differentiation among manufacturers. Sandoz has established a strong presence in the UK Biosimilar Contract Manufacturing Market, leveraging its expertise in biologics and a robust portfolio of biosimilar products. Its strengths lie in its advanced manufacturing facilities, which are compliant with international standards, enabling the company to produce high-quality biosimilars. Sandoz has positioned itself as a leader through continuous innovation and by fostering partnerships that enhance its development capabilities. The company's focus on sustainability and efficiency in manufacturing processes further contributes to its competitive edge. Additionally, Sandoz has successfully built a solid reputation within the healthcare community in the UK, attributed to its commitment to patient-centric approaches and collaboration with healthcare providers to ensure broader access to affordable therapies. Novartis plays a pivotal role in the UK Biosimilar Contract Manufacturing Market, primarily driven by its comprehensive portfolio of biosimilars that encompasses a range of therapeutic areas. The company is known for its strong research and development capabilities, which allow it to produce high-quality biosimilar products tailored to specific market needs. Novartis has gained a significant foothold in the UK through strategic mergers and acquisitions that have bolstered its market presence, allowing it to enhance its manufacturing capabilities and distribution networks. The strengths of Novartis lie in its innovative approach, combined with a dedication to maintaining regulatory compliance and quality assurance throughout its manufacturing processes. The company's various key products and services reflect its commitment to addressing unmet medical needs while ensuring that it remains a competitive force in the rapidly evolving landscape of the UK biosimilar market. #### **Key Companies in the UK Biosimilar Contract Manufacturing Market Include** ### **UK Biosimilar Contract Manufacturing Market Industry Developments** Recent developments in the UK Biosimilar Contract Manufacturing Market have been noteworthy, particularly as companies like Sandoz and Novartis continue to expand their roles in biosimilars. AstraZeneca has been advancing its partnership strategies, particularly in the context of its oncology biosimilars. The market has seen significant growth, with the valuation of companies such as Merck KGaA and Teva Pharmaceuticals steadily rising, influenced by the increasing demand for cost-effective biologics. This growth trajectory is impacting the overall market dynamics, compelling organizations to enhance their manufacturing capabilities. In terms of mergers and acquisitions, notable activity includes Pfizer's acquisition of a biologics manufacturing facility in the UK reported in March 2023, which is expected to bolster their production capacity of biosimilars. Also, in August 2022, Amgen announced a collaboration with Fujifilm Diosynth Biotechnologies to optimize the production processes for biosimilars, further emphasizing the collaborative efforts within the industry. Overall, these developments signify a robust and evolving landscape in the UK Biosimilar Contract Manufacturing Market, reflecting the increasing emphasis on biopharmaceutical innovation and efficiency. ### **UK Biosimilar Contract Manufacturing Market Segmentation Insights** #### **Biosimilar Contract Manufacturing Market Product Outlook** #### **Biosimilar Contract Manufacturing Market Production Technology Outlook** #### **Biosimilar Contract Manufacturing Market Application Outlook** ## Market Drivers ### Growing Patient Population The expanding patient population in the UK, particularly those suffering from chronic diseases, is a significant driver for the biosimilar contract-manufacturing market. With an estimated 15 million individuals living with chronic conditions, the demand for effective and affordable treatment options is escalating. Biosimilars, which mimic the efficacy of original biologics at a lower cost, are becoming increasingly vital in addressing this healthcare challenge. The NHS's commitment to improving patient access to these therapies further supports the growth of the biosimilar contract-manufacturing market. As more patients require treatment, the need for contract manufacturers to produce high-quality biosimilars will likely intensify, creating opportunities for innovation and collaboration within the industry. This trend indicates a robust future for the biosimilar contract-manufacturing market as it adapts to meet the needs of a growing patient demographic. ### Increasing Healthcare Expenditure The rising healthcare expenditure in the UK is a pivotal driver for the biosimilar contract-manufacturing market. As the National Health Service (NHS) allocates more funds towards innovative therapies, the demand for cost-effective biosimilars is likely to surge. In 2025, healthcare spending in the UK is projected to reach approximately £200 billion, indicating a robust investment in pharmaceuticals. This financial commitment encourages the development and manufacturing of biosimilars, as they offer a more affordable alternative to expensive biologics. Consequently, contract manufacturers are positioned to capitalize on this trend, providing essential services to pharmaceutical companies aiming to enter the biosimilar market. The increasing focus on budget-friendly healthcare solutions suggests a promising landscape for the biosimilar contract-manufacturing market, as stakeholders seek to balance quality and cost. ### Regulatory Support for Biosimilars Regulatory support for biosimilars in the UK is a crucial driver for the biosimilar contract-manufacturing market. The Medicines and Healthcare products Regulatory Agency (MHRA) has established a clear framework for the approval of biosimilars, which fosters confidence among manufacturers and investors. This supportive regulatory environment is expected to facilitate the entry of new biosimilars into the market, with an anticipated increase in approvals by 20% over the next few years. As more biosimilars gain regulatory clearance, the demand for contract manufacturing services is likely to rise, as pharmaceutical companies seek reliable partners to produce these products. The proactive stance of regulatory bodies not only enhances market stability but also encourages innovation within the biosimilar contract-manufacturing market, paving the way for future growth. ### Technological Advancements in Production Technological advancements in biomanufacturing processes are transforming the biosimilar contract-manufacturing market. Innovations such as single-use bioreactors and continuous manufacturing techniques are enhancing production efficiency and reducing costs. In the UK, the adoption of these technologies is expected to increase, with a projected growth rate of 10% in the biomanufacturing sector by 2026. These advancements not only streamline production but also improve the scalability of biosimilar manufacturing, allowing companies to respond swiftly to market demands. As contract manufacturers integrate cutting-edge technologies, they can offer more competitive pricing and higher quality products, thereby attracting pharmaceutical companies looking to develop biosimilars. This technological evolution is likely to play a crucial role in shaping the future landscape of the biosimilar contract-manufacturing market. ### Rising Competition Among Biopharmaceutical Companies The increasing competition among biopharmaceutical companies in the UK is driving the growth of the biosimilar contract-manufacturing market. As more companies enter the biosimilar space, the need for efficient and cost-effective manufacturing solutions becomes paramount. This competitive landscape is prompting firms to seek partnerships with contract manufacturers that can provide specialized expertise and scalable production capabilities. The biosimilar market is projected to grow at a CAGR of 15% through 2027, indicating a robust opportunity for contract manufacturers to expand their services. As biopharmaceutical companies strive to differentiate their products, the demand for high-quality biosimilars produced by contract manufacturers is likely to increase. This trend suggests a dynamic and evolving biosimilar contract-manufacturing market, where collaboration and innovation are essential for success. ## Future Outlook The [Biosimilar Contract Manufacturing Market](https://www.marketresearchfuture.com/reports/biosimilar-contract-manufacturing-market-11903) is projected to grow at 18.9% CAGR from 2025 to 2035, driven by increasing demand for cost-effective biologics and regulatory support. **New opportunities:** - Expansion of manufacturing capabilities for complex biosimilars - Strategic partnerships with biotech firms for co-development - Investment in advanced bioprocessing technologies to enhance efficiency By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in biopharmaceutical manufacturing. ## Segment Insights ### By Product: Recombinant Glycosylated Proteins (Largest) vs. Recombinant Non-glycosylated Proteins (Fastest-Growing) In the UK biosimilar contract-manufacturing market, recombinant glycosylated proteins hold the largest market share, primarily due to their extensive applications in therapeutic areas such as oncology and autoimmune diseases. These products are favored for their enhanced biocompatibility and efficacy, contributing to their dominance in contract manufacturing agreements. On the other hand, recombinant non-glycosylated proteins are perceived as the fastest-growing segment within this market. Their growth can be attributed to increased research and development activities aimed at scaling up production capabilities and lower manufacturing costs. Additionally, the rising demand for these proteins in various therapeutic applications emphasizes their potential for expansion in the coming years. Recombinant Glycosylated Proteins (Dominant) vs. Recombinant Non-glycosylated Proteins (Emerging) Recombinant glycosylated proteins are a staple in the UK biosimilar contract-manufacturing market, recognized for their structural complexity and therapeutic efficacy. They play a crucial role in treating chronic illnesses, leading to their significant demand among pharmaceutical companies. In contrast, recombinant non-glycosylated proteins are emerging as a promising alternative due to their simpler structure and cost-effective production processes. This segment is gaining traction, particularly for applications that do not require glycosylation, presenting new opportunities for manufacturers to innovate and cater to a broader range of therapeutic needs. ### By Production Technology: Mammalian (Largest) vs. Non-Mammalian (Fastest-Growing) In the UK biosimilar contract-manufacturing market, Mammalian technology holds a significant share, reflecting its longstanding application in the development of effective therapeutics. This type of production is preferred for complex protein structures, which are crucial for biosimilar efficacy. Meanwhile, Non-Mammalian technology, although currently smaller in market share, is experiencing rapid adoption due to its cost advantages and scalability, appealing to manufacturers looking to optimize production costs while maintaining quality. The growth trends in the production technology segment highlight an increasing shift towards Non-Mammalian systems driven by advancements in fermentation processes and genetic engineering. As demand for biosimilars rises, the flexibility and efficiency offered by Non-Mammalian production are becoming critical. This trend is supported by a growing focus on innovation, sustainability, and the need for rapid market entry, positioning Non-Mammalian technology as a key player in future developments. Technology: Mammalian (Dominant) vs. Non-Mammalian (Emerging) Mammalian production technology remains dominant in the UK biosimilar contract-manufacturing market, primarily due to its ability to produce complex biologics with post-translational modifications essential for functionality. This technology has a well-established ecosystem, comprising various cell lines such as CHO and NS0 that have been extensively characterized. On the other hand, Non-Mammalian technology is emerging as a viable alternative, leveraging prokaryotic or lower eukaryotic systems to produce biosimilars. This approach often allows for faster production times and lower manufacturing costs. As the regulatory landscape evolves and technology advances, both Mammalian and Non-Mammalian platforms will play critical roles, catering to diverse needs within biosimilar production. ### By Application: Oncology (Largest) vs. Blood Disorders (Fastest-Growing) The UK biosimilar contract-manufacturing market is significantly influenced by various application segments, with Oncology holding a substantial share. This segment benefits from an increasing prevalence of cancer and a growing focus on personalized medicine. Blood Disorders follow closely, showcasing a rapidly expanding footprint thanks to innovations in treatment options and a rising number of patients requiring long-term therapies. Growth trends in this sector are driven by advancements in biopharmaceutical manufacturing technologies which enhance efficiency and reduce costs. The demand for cost-effective treatments is propelling the uptake of biosimilars in chronic conditions, particularly in the fields of Chronic & Autoimmune Disorders and Rheumatoid Arthritis. This aligns with the broader healthcare trend towards value-based care, where healthcare providers are seeking budget-friendly solutions to meet patient needs. Oncology: Dominant vs. Blood Disorders: Emerging Oncology stands as a dominant application within the UK biosimilar contract-manufacturing market, emphasizing its role in addressing the critical healthcare needs of cancer patients. This segment is characterized by strong partnerships between manufacturers and pharmaceutical companies to facilitate faster approvals and market access. Conversely, Blood Disorders represent an emerging segment, driven by the evolving landscape of therapeutic interventions. The rapid development of biosimilar therapies for conditions such as hemophilia and sickle cell disease indicates a robust future. Both segments are critical, yet Oncology's stronghold is being increasingly challenged by the dynamic growth observed in Blood Disorders, heralding a shift in market focus. ## Competitive Benchmarking The biosimilar contract-manufacturing market is currently characterized by a dynamic competitive landscape, driven by increasing demand for cost-effective biologics and the need for rapid market entry. Key players such as Samsung Biologics (KR), Lonza Group (CH), and Boehringer Ingelheim (DE) are strategically positioned to leverage their extensive manufacturing capabilities and technological expertise. Samsung Biologics (KR) has focused on expanding its production capacity, which appears to enhance its competitive edge in meeting the growing demand for biosimilars. Meanwhile, Lonza Group (CH) emphasizes innovation through its advanced manufacturing technologies, aiming to streamline production processes and reduce time-to-market for its clients. Boehringer Ingelheim (DE) has adopted a partnership-driven approach, collaborating with various biotech firms to bolster its service offerings and expand its market reach.The market structure is moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce logistics costs and optimizing supply chains to enhance efficiency. This collective influence of major players fosters a competitive environment where agility and responsiveness to market needs are paramount. The interplay of these strategies indicates a trend towards consolidation, as companies seek to enhance their operational capabilities and market presence. In October Fujifilm Diosynth Biotechnologies (JP) announced the opening of a new state-of-the-art facility in the UK, aimed at increasing its production capacity for biosimilars. This strategic move is likely to position Fujifilm as a formidable competitor in the market, enabling it to cater to the rising demand for biologics while enhancing its operational efficiency. The facility is expected to incorporate advanced manufacturing technologies, which may further solidify Fujifilm's reputation for quality and reliability in the biosimilar sector. In September Catalent (US) entered into a strategic partnership with a leading biotech firm to co-develop a new biosimilar product. This collaboration underscores Catalent's commitment to innovation and its proactive approach to expanding its product portfolio. By aligning with biotech innovators, Catalent is likely to enhance its competitive positioning and accelerate the development of new therapies, thereby responding effectively to market demands. In August Wuxi Biologics (CN) announced a significant investment in its UK operations, focusing on expanding its capabilities in biologics manufacturing. This investment is indicative of Wuxi's strategy to strengthen its foothold in the European market, potentially allowing it to better serve its clients with localized production. Such moves may enhance Wuxi's competitive advantage by improving supply chain reliability and reducing lead times for customers. As of November the competitive trends in the biosimilar contract-manufacturing market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and enhancing operational efficiencies. Looking ahead, the competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, supply chain reliability, and innovative solutions that meet the complex needs of the market. ## Recent News & Developments Recent developments in the UK Biosimilar Contract Manufacturing Market have been noteworthy, particularly as companies like Sandoz and Novartis continue to expand their roles in biosimilars. AstraZeneca has been advancing its partnership strategies, particularly in the context of its oncology biosimilars. The market has seen significant growth, with the valuation of companies such as Merck KGaA and Teva Pharmaceuticals steadily rising, influenced by the increasing demand for cost-effective biologics. This growth trajectory is impacting the overall market dynamics, compelling organizations to enhance their manufacturing capabilities. In terms of mergers and acquisitions, notable activity includes Pfizer's acquisition of a biologics manufacturing facility in the UK reported in March 2023, which is expected to bolster their production capacity of biosimilars. Also, in August 2022, Amgen announced a collaboration with Fujifilm Diosynth Biotechnologies to optimize the production processes for biosimilars, further emphasizing the collaborative efforts within the industry. Overall, these developments signify a robust and evolving landscape in the UK Biosimilar Contract Manufacturing Market, reflecting the increasing emphasis on biopharmaceutical innovation and efficiency. ## Report Scope | MARKET SIZE 2024 | 541.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 643.25(USD Million) | | MARKET SIZE 2035 | 3632.14(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.9% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Rentschler Biopharma (DE), KBI Biopharma (US), Amgen (US) | | Segments Covered | Product, Production Technology, Application | | Key Market Opportunities | Growing demand for cost-effective biosimilars drives innovation in biosimilar contract-manufacturing market. | | Key Market Dynamics | Rising demand for cost-effective biosimilars drives competitive contract-manufacturing partnerships in the UK market. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What was the market valuation of the UK biosimilar contract-manufacturing market in 2024?** A: The market valuation was $541.0 Million in 2024. **Q: What is the projected market valuation for the UK biosimilar contract-manufacturing market by 2035?** A: The projected valuation for 2035 is $3632.14 Million. **Q: What is the expected CAGR for the UK biosimilar contract-manufacturing market during the forecast period 2025 - 2035?** A: The expected CAGR is 18.9% during the forecast period 2025 - 2035. **Q: Which companies are considered key players in the UK biosimilar contract-manufacturing market?** A: Key players include Samsung Biologics, Lonza Group, Boehringer Ingelheim, and Fujifilm Diosynth Biotechnologies. **Q: What are the main product segments in the UK biosimilar contract-manufacturing market?** A: Main product segments include Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins. **Q: What was the market size for Recombinant Non-glycosylated Proteins in 2024?** A: The market size for Recombinant Non-glycosylated Proteins was $200.0 Million in 2024. **Q: What is the projected market size for Mammalian production technology by 2035?** A: The projected market size for Mammalian production technology is $2500.0 Million by 2035. **Q: Which application segment had the highest market size in 2024?** A: The Oncology application segment had the highest market size at $108.2 Million in 2024. **Q: What is the expected growth for Chronic & Autoimmune Disorders in the UK biosimilar contract-manufacturing market?** A: The expected market size for Chronic & Autoimmune Disorders is projected to reach $1080.0 Million by 2035. **Q: How does the market size for Non-Mammalian production technology compare to Mammalian production technology?** A: In 2024, Non-Mammalian production technology was valued at $141.0 Million, significantly lower than Mammalian's $400.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-biosimilar-contract-manufacturing-market-51865*